Bolt Biotherapeutics, Inc.
BOLT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 20.2% | 47.6% | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 86.6% | 100% | 100% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -316% | -491.3% | -958.8% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -329.4% | -474.6% | -903.4% | – |
| EPS Diluted | -3.722 | -4.46 | -0.29 | -0.42 |
| % Growth | 16.5% | -1,437.9% | 31% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |